Author details

Full Name

Cornelia Eckert

Affiliation

ORCID

Career Start Year

2000

Papers

116

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37100882	The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome.		2023
36416169	X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.	EMBO Molecular Medicine	2023
36651980	Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia.		2023
37019990	The KMT2A recombinome of acute leukemias in 2023.	Leukemia	2023
36482128	Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.		2023
34757015	Advanced Minimal Residual Disease Monitoring for Acute Lymphoblastic Leukemia with Multiplex Mediator Probe PCR.	Journal of Molecular Diagnostics	2022
35522562	CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment.	Journal of Pathology	2022
35585141	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.	Leukemia	2022
35452517	Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.	Blood	2022
35436854	An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse.	BMC Genomic Data	2022
35933523	Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.	Leukemia	2022
35800767	The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.	iScience	2022
35732190	Supramolecular assembly of GSK3Î± as a cellular response to amino acid starvation.	Molecular Cell	2022
35482538	Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.	Pediatric Blood and Cancer	2022
34597466	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.	Pediatr Blood Cancer	2022
35122027	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.	Nat Cancer	2021
34010787	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.	Eur J Cancer	2021
33580201	Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome.	Leukemia	2021
33651091	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.	JAMA - Journal of the American Medical Association	2021
32499245	Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia.	Haematologica	2021
34442335	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.	J Pers Med	2021
34610112	Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.	Blood advances	2021
31304977	Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model.	Int J Cancer	2020
31971569	Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.	Blood	2020
32309784	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.	HemaSphere	2020
33479702	Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment is dependent on Stearoyl CoA desaturase.	Nature Cancer	2020
32755029	Chromatin accessibility landscape of pediatric T-lymphoblastic leukemia and human T-cell precursors.	EMBO Mol Med	2020
32591499	Repurposing anthelmintic agents to eradicate resistant leukemia.	Blood Cancer Journal	2020
33027529	TNFR2 is required for RIP1-dependent cell death in human leukemia.	Blood advances	2020
32853382	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.	Blood Adv	2020
32668722	Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia.	Cancers	2020
31073076	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.	Haematologica	2020
30714092	Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse.	British Journal of Haematology	2019
31648313	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.	Blood Adv	2019
31644328	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.	J Clin Oncol	2019
31714961	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.	Blood advances	2019
30642353	Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.	J Hematol Oncol	2019
31089287	Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL.	Bone Marrow Transplant	2019
31034759	High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.	Pediatr Blood Cancer	2019
30862934	Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.	Sci Rep	2019
30842609	PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.	Leukemia	2019
29498923	IKZF1<sup>plus</sup> Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.	J Clin Oncol	2018
30389682	PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia.	EMBO Mol Med	2018
29489754	The landscape of genomic alterations across childhood cancers.	Nature	2018
28122742	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.	Blood	2017
28775158	Targeted therapy of CNS leukemia?	Blood	2017
28771662	Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.	Br J Haematol	2017
28461505	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.	Proc Natl Acad Sci U S A	2017
28360149	mutation, alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.	Haematologica	2017
27899802	Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.	Leukemia	2017